PubRank

Hans-Peter Volz

Author PubWeight™ 13.25‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Neuroanatomy of "hearing voices": a frontotemporal brain structural abnormality associated with auditory hallucinations in schizophrenia. Cereb Cortex 2004 1.46
2 Processing of temporal information and the basal ganglia: new evidence from fMRI. Exp Brain Res 2002 1.35
3 The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 2009 1.23
4 Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials. Wien Med Wochenschr 2010 0.99
5 Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial. Int Clin Psychopharmacol 2010 0.96
6 Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disord 2009 0.88
7 Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs 2013 0.88
8 Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression. Int Clin Psychopharmacol 2010 0.87
9 Rare variants of the gene encoding the potassium chloride co-transporter 3 are associated with bipolar disorder. Int J Neuropsychopharmacol 2005 0.85
10 Metabolic mapping using 2D 31P-MR spectroscopy reveals frontal and thalamic metabolic abnormalities in schizophrenia. Neuroimage 2006 0.84
11 Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity. Eur Arch Psychiatry Clin Neurosci 2009 0.81
12 [Acute Paranoid Symptoms Following Intramuscular Injection of Nandrolone] Psychiatr Prax 2003 0.81
13 Combined measurement of event-related potentials (ERPs) and fMRI. Acta Neurobiol Exp (Wars) 2003 0.78
14 Do neuroleptics alter the cerebral intracellular pH value in schizophrenics?-a (31)P-MRS study on three different patient groups. Psychiatry Res 2002 0.77
15 Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities. World J Biol Psychiatry 2006 0.75
16 Silexan in generalized anxiety disorder: investigation of the therapeutic dosage range in a pooled data set. Int Clin Psychopharmacol 2017 0.75
17 [Laif 900 in treatment of depression. Proven reliability in first line therapy]. MMW Fortschr Med 2010 0.75
18 [Acute schizophreniform disorder in Hashimoto disease]. Psychiatr Prax 2003 0.75
19 [Not Available]. MMW Fortschr Med 2016 0.75
20 Input dysfunction and beyond--an evaluation of CPT components. Schizophr Res 2002 0.75
21 The "DGPPN-Cohort": A national collaboration initiative by the German Association for Psychiatry and Psychotherapy (DGPPN) for establishing a large-scale cohort of psychiatric patients. Eur Arch Psychiatry Clin Neurosci 2013 0.75
22 The best next drug in the course of generalized anxiety disorders: the "PN-GAD-algorithm". Int J Psychiatry Clin Pract 2013 0.75
23 [Acute paranoid psychotic symptoms after i.m. injection of nandrolone]. Psychiatr Prax 2003 0.75